TVTX
HEALTHCARETravere Therapeutics Inc
$44.76-0.04 (-0.09%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TVTX Today?
No stock-specific AI insight has been generated for TVTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$13.88$48.61
$44.76
Fundamentals
Market Cap$4.2B
P/E Ratio—
EPS$-0.50
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding93.0M
TVTX News
21 articles- Discover May 2026's Top Stocks Estimated Below Intrinsic ValueYahoo Finance·May 8, 2026
- 3 Stocks That Could Be Trading Up To 46.1% Below Their Estimated Intrinsic ValueYahoo Finance·May 8, 2026
- Travere Therapeutics to Participate at Upcoming Investor Conferences - May 7, 2026BioSpace·May 8, 2026
- Travere Therapeutics to Participate at Upcoming Investor ConferencesYahoo Finance·May 7, 2026
- Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible NotesYahoo Finance·May 7, 2026
- Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible NotesYahoo Finance·May 5, 2026
- 3 Stocks Estimated To Be Trading Up To 49.9% Below Intrinsic ValueYahoo Finance·May 5, 2026
- 3 Stocks With Estimated Discounts Up To 44.8% Offering Value OpportunitiesYahoo Finance·May 5, 2026
- Travere Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 5, 2026
- Travere Therapeutics Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Travere (TVTX) Q1 2026 Earnings TranscriptMotley Fool·May 4, 2026
- Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 4, 2026
- Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 4, 2026
- MercadoLibre And 2 Other Stocks That May Be Priced Below Their Estimated ValueYahoo Finance·May 4, 2026
- Datadog And Two Other Stocks That Could Be Trading Below Fair Value EstimatesYahoo Finance·May 4, 2026
- Travere Therapeutics (TVTX) Is Up 8.9% After Stronger Quarter And Insider Sales Activity – Has The Bull Case Changed?Yahoo Finance·May 4, 2026
- XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?Yahoo Finance·Apr 28, 2026
- Travere Therapeutics to Report First Quarter 2026 Financial ResultsYahoo Finance·Apr 27, 2026
- Royalty Powerhouse: Ligand And Xoma Unite In $739 Million DealYahoo Finance·Apr 27, 2026
- Travere Therapeutics Inc. (TVTX): First-Mover Advantage Is Massive MoatYahoo Finance·Apr 27, 2026
- Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?Yahoo Finance·Apr 24, 2026
All 21 articles loaded
Price Data
Open$43.77
Previous Close$44.80
Day High$44.50
Day Low$42.50
52 Week High$48.61
52 Week Low$13.88
52-Week Range
$13.88$48.61
$44.76
Fundamentals
Market Cap$4.2B
P/E Ratio—
EPS$-0.50
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin-0.0%
Debt / Equity—
Trading
Volume2.4M
Avg Volume (10D)—
Shares Outstanding93.0M
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—